Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;34(9):833-45.
doi: 10.1007/s40273-016-0410-3.

Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer

Affiliations

Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer

Pieter T de Boer et al. Pharmacoeconomics. 2016 Sep.

Abstract

Background: Transparent reporting of validation efforts of health economic models give stakeholders better insight into the credibility of model outcomes. In this study we reviewed recently published studies on seasonal influenza and early breast cancer in order to gain insight into the reporting of model validation efforts in the overall health economic literature.

Methods: A literature search was performed in Pubmed and Embase to retrieve health economic modelling studies published between 2008 and 2014. Reporting on model validation was evaluated by checking for the word validation, and by using AdViSHE (Assessment of the Validation Status of Health Economic decision models), a tool containing a structured list of relevant items for validation. Additionally, we contacted corresponding authors to ask whether more validation efforts were performed other than those reported in the manuscripts.

Results: A total of 53 studies on seasonal influenza and 41 studies on early breast cancer were included in our review. The word validation was used in 16 studies (30 %) on seasonal influenza and 23 studies (56 %) on early breast cancer; however, in a minority of studies, this referred to a model validation technique. Fifty-seven percent of seasonal influenza studies and 71 % of early breast cancer studies reported one or more validation techniques. Cross-validation of study outcomes was found most often. A limited number of studies reported on model validation efforts, although good examples were identified. Author comments indicated that more validation techniques were performed than those reported in the manuscripts.

Conclusions: Although validation is deemed important by many researchers, this is not reflected in the reporting habits of health economic modelling studies. Systematic reporting of validation efforts would be desirable to further enhance decision makers' confidence in health economic models and their outcomes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a Seasonal influenza literature search. b Early breast cancer literature search
Fig. 2
Fig. 2
Model validation performances of 53 studies on seasonal influenza, as reported in publications, using the classification of the AdViSHE tool. Numbers above the bars represent absolute numbers of studies. AdViSHE Assessment of the Validation Status of Health Economic decision models

Comment in

  • Model Validation: Has it's Time Come?
    Karnon J. Karnon J. Pharmacoeconomics. 2016 Sep;34(9):829-31. doi: 10.1007/s40273-016-0415-y. Pharmacoeconomics. 2016. PMID: 27225253 No abstract available.

References

    1. Caro JJ, Briggs AH, Siebert U, Kuntz KM, ISPOR-SMDM modeling good research practices task force Modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health. 2012;15:796–803. doi: 10.1016/j.jval.2012.06.012. - DOI - PubMed
    1. Cash D, Clark WC, Alcock F, Dickson NM, Eckley N, Jäger J. Salience, credibility, legitimacy and boundaries: linking research, assessment and decision making. RWP02-046. Cambridge, MA: John F. Kennedy School of Government, Harvard University; 2002.
    1. van Voorn GA, Vemer P, Hamerlijnck D, Ramos IC, Teunissen GJ, Al M, Feenstra TL. The Missing Stakeholder Group: why patients should be involved in health economic modelling. Appl Health Econ Health Policy. 2016;14:129–133. doi: 10.1007/s40258-015-0200-7. - DOI - PMC - PubMed
    1. Dams J, Bornschein B, Reese JP, Conrads-Frank A, Oertel WH, Siebert U, et al. Modelling the cost effectiveness of treatments for Parkinson’s disease: a methodological review. Pharmacoeconomics. 2011;29:1025–1049. doi: 10.2165/11587110-000000000-00000. - DOI - PubMed
    1. Bolin K. Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models. Pharmacoeconomics. 2012;30:551–564. doi: 10.2165/11590120-000000000-00000. - DOI - PubMed

Publication types